-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Silence Therapeutics Begins Exclusive Nasdaq Trading
Silence Therapeutics Begins Exclusive Nasdaq Trading
Silence Therapeutics Begins Exclusive Nasdaq Trading
30 November 2021
LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the cancellation of admission of its ordinary shares of nominal value £0.05 each (the "Ordinary Shares") to trading on AIM (the "AIM Delisting") was effective from 7:00 a.m. (London time) today.
Silence's American Depositary Shares, each representing three Ordinary Shares (the "ADSs"), are now listed and only tradeable on the Nasdaq Global Market ("Nasdaq") under the ticker symbol SLN.
Mark Rothera, President and Chief Executive Officer of Silence, said: "Listing solely on the Nasdaq supports our strategy to attract high quality U.S. institutional healthcare funds as Silence gears up for the next phase of growth based on maximizing our proprietary mRNAi GOLD™ platform."
As previously announced, the last day of trading of the Company's Ordinary Shares on AIM was 29 November 2021. Information about the process to deposit Ordinary Shares for delivery of ADSs was provided in the announcement and circular published by the Company on 15 October 2021 and is also available on the Company's website at www.silence-therapeutics.com/investors/AIM-Delisting.
Enquiries:
Silence Therapeutics plc Gem Hopkins, Head of IR & Corporate Communications | Tel: +1 (646) 637-3208 |
European PR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com | Tel: +44 (0) 20 3709 5700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit .
Silence Therapeutics Begins Exclusive Nasdaq Trading
沉默疗法 开始 独家纳斯达克交易
30 November 2021
2021年11月30日
LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the cancellation of admission of its ordinary shares of nominal value £0.05 each (the "Ordinary Shares") to trading on AIM (the "AIM Delisting") was effective from 7:00 a.m. (London time) today.
伦敦,沉默治疗公司,纳斯达克:SLN(“静默或“The”公司)是发现、开发和交付新的短干扰核糖核酸(SiRNA)疗法的领先者,用于治疗有重大未得到满足的医疗需求的疾病。该公司今天宣布,取消其每股面值为GB 0.05的普通股的认购(普通股“)在AIM(The”)上进行交易AIM退市“)已于今日上午7时(伦敦时间)起生效。
Silence's American Depositary Shares, each representing three Ordinary Shares (the "ADSs"), are now listed and only tradeable on the Nasdaq Global Market ("Nasdaq") under the ticker symbol SLN.
沉默的美国存托股份,每股相当于三股普通股(“美国存托凭证),现已上市,只能在纳斯达克全球市场交易(纳斯达克“)在股票代码SLN下。
Mark Rothera, President and Chief Executive Officer of Silence, said: "Listing solely on the Nasdaq supports our strategy to attract high quality U.S. institutional healthcare funds as Silence gears up for the next phase of growth based on maximizing our proprietary mRNAi GOLD™ platform."
沉默公司总裁兼首席执行官马克·罗瑟拉说:“在沉默公司基于最大限度地利用我们专有的mRNAi黄金™平台的基础上,为下一阶段的增长做准备,仅在纳斯达克上市支持我们吸引高质量美国机构医疗基金的战略。”
As previously announced, the last day of trading of the Company's Ordinary Shares on AIM was 29 November 2021. Information about the process to deposit Ordinary Shares for delivery of ADSs was provided in the announcement and circular published by the Company on 15 October 2021 and is also available on the Company's website at www.silence-therapeutics.com/investors/AIM-Delisting.
一如先前公布,本公司普通股于AIM的最后交易日为2021年11月29日。有关缴存普通股以供交付美国存托凭证程序的资料,载于本公司于2021年10月15日刊发的公告及通函,亦可于本公司网站www.silence-therapeutics.com/investors/AIM-Delisting.查阅。
Enquiries:
查询:
Silence Therapeutics plc Gem Hopkins, Head of IR & Corporate Communications |
Tel: +1 (646) 637-3208 |
European PR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com |
Tel: +44 (0) 20 3709 5700 |
沉默治疗公司 吉姆·霍普金斯(Gem Hopkins),投资者关系和企业公关主管 |
电话:+1(646)637-3208 |
欧洲公关 Consilium战略传播 玛丽-简·埃利奥特/克里斯·威尔士/安吉拉·格雷 邮箱:silenceTreateutics@conconlium-comms.com |
电话:+44(0)2037095700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit .
关于沉默疗法
沉默治疗公司正在开发新一代药物,方法是利用人体自然的RNA干扰(RNAi)机制,抑制特定靶基因的表达,这些基因被认为在具有重大未得到满足的医疗需求的疾病的病理中发挥作用。Silent公司专有的mRNAi金™平台可以用来制造精确针对和沉默肝脏中与疾病相关的基因的siRNA,这代表着一个巨大的机会。SILE公司全资拥有的候选产品包括SLN360和SLN124。SLN360旨在满足在降低天生高水平脂蛋白(A)人群心血管风险方面的高和普遍的未得到满足的医疗需求,SLN124旨在解决铁负荷贫血问题。沉默公司还与阿斯利康公司、美林制药公司和汉索制药公司等公司保持着持续的研发合作。有关更多信息,请访问。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧